Sun, Mar 1, 2015, 11:26 AM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

Qihoo 360 Technology Co. Ltd. Message Board

tnk.shorting 2 posts  |  Last Activity: Jan 15, 2015 2:26 PM Member since: Feb 29, 2012
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • tnk.shorting by tnk.shorting Jan 15, 2015 2:26 PM Flag

    As some old timers here may recall, Dirk gave SYNERGY a thumbs down prior to readout. I got numerous thumbs down here for relaying Dirk's negative tweet, but Dirk ended up being right. Since I never was a custirsen believer, I actually bought more OGXI shares on the basis of apatorsen's potential - which is why I'm not happy about Dirk's latest tweet about OGXI,. Does anyone know what "recent data" Dirk is referring to?

    Dirk Haussecker ‏@RNAiAnalyst 3h3 hours ago
    @WilliamGerber1 @redacre beware $ogxi, recent $ISIS data support that very hard to get knockdown in tumor cells (unlike microenvironment).

  • Reply to

    It supposed to be 'GOOD' news today

    by lefty_rosenthal7 Dec 19, 2014 4:56 PM
    tnk.shorting tnk.shorting Dec 19, 2014 6:29 PM Flag

    IMO, today was not good news. It appears that the trial failed (overall HR too high). As with SYNERGY, they drilled down into the data to look for benefits among subgroups, and they found what they were looking for. The benefit they found may or may not be real. However, I'm not sure how they'll know for sure without another lengthy and expensive trial. Who's going to pay for it?

    I'd like to see more data - specifically, PFS and OS data expressed in months: How much longer did the treatment arm and subgroup survive? If the benefit of Apatorsen was short-lived, who would want to invest in a Phase 3 trial?

    Fortunately, there are many more Phase 2 Apatorsen (and a few more Custirsen) trials that can still move the ball downfield in the event of good news. But as for today, I'm not sure why Needham felt this was a reason to encourage investors to buy. I'm already long OGXI, but won't be buying more or selling until management gives us a more complete picture of how the Borealis-1 patients fared.

45.73-1.26(-2.68%)Feb 27 4:03 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Herbalife Ltd.
NYSEFri, Feb 27, 2015 4:01 PM EST
Auspex Pharmaceuticals, Inc.
NASDAQFri, Feb 27, 2015 4:00 PM EST